Key result
Lp(a) may self-regulate its fibrinolysis interference by reducing platelet aggregation.
Answers are grounded in this paper and cite their sources.
This review highlights the complex and potentially self-regulating role of Lp(a) in thrombosis, where its anti-fibrinolytic properties may be counterbalanced by its ability to reduce platelet aggregation.
Lipoprotein (a) (Lp (a)) may be pro-thrombotic in humans due to its apolipoprotein (a) (apo(a))-mediated decreases in fibrinolysis. Such decreased fibrinolysis arises putatively from interference with plasminogen conversion to plasmin due to the considerable homology between apolipoprotein (a) and plasminogen. However, in vitro, most studies have shown that human Lp (a) decreases agonist-stimulated platelet aggregation while in vivo it appears to decrease aggregation as implied by increased bleeding times with higher blood serum concentrations of Lp(a). Lp (a) binding to platelets mediated by apo (a) increases platelet intracellular c-AMP levels in resting platelets, and decreases platelet production of thromboxane A2 and fibrinogen binding to platelets all of which reduce platelet aggregation. One, though not the only, explanation of these conflicting data may be that Lp(a) self-regulates its interference with fibrinolysis by reducing platelet aggregation and platelet binding of fibrinogen and hence the degree of requirement for fibrinolysis. However, it is concluded more in vivo work needs to be done to fully understand whether, if at all, Lp(a) in varying concentrations and isoforms, favours reduced platelet aggregation or fibrinolysis.
No takes yet. Share an insight, caveat, or question.
D. Edward Barre (2007) reported a review. Lipoprotein (a) was evaluated. Lipoprotein (a) may self-regulate its interference with fibrinolysis by reducing platelet aggregation, though conflicting in vitro and in vivo data necessitate further in vivo studies.
Synapse has enriched 10 related papers. Consider them for comparative context: